Structure Therapeutics Inc.
GPCR · Pharmaceutical Preparations · 213.2M shares · +239%/yr ↑ dilution · EDGAR filings ↗
Grade
D46Clinical/early-stage biotech — obesity/metabolic clinical, very heavy burn ($226M), very cash-rich.
Strengths
- Liquidity — current ratio 24.8 (97th)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- Exec changeRecent 8-K item 5.02 8-K ↗
- Cash burnNegative free cash flow (-225.8M)
- Chronic dilutionShare count +239%/yr over 2y (dilution, book value/share -71%)
- Strong balance sheetStrong balance sheet — $1.4B cash & investments, ~26 quarters of runway
- Trial resultPositive trial readout — primary endpoint met (8-K) 8-K ↗
- Notable holderHeld by 5 notable fund(s): FMR LLC, GOLDMAN SACHS GROUP INC, CITADEL ADVISORS LLC +2 more (as of 2026-03-31)
- AccumulatingInstitutional holders rose 11→12 QoQ (2025-12-31→2026-03-31)
- Trial readout soonUpcoming trial readout ~2026-08 — PHASE2 · Obesity, Overweight, or Chronic Weight Management
Key metrics
Return on equity
-9.3%
Return on assets
-8.9%
Current ratio
24.8×
Free cash flow
-$226M
Tangible book value
$1.5B
Cash & investments
$1.4B
Cash runway
26q
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-15 | Lang Matthew | Grant | 185K | — |
| 2026-03-19 | Ma Yingli | Grant | 33K | — |
| 2026-03-19 | Coll Crespo Blas | Grant | 76K | — |
| 2026-03-19 | Yoon Jun | Grant | 104K | — |
| 2026-03-19 | Hall Ashley | Grant | 48K | — |
| 2026-03-19 | Stevens Raymond C | Grant | 260K | — |
| 2026-03-19 | Lin Xichen | Grant | 43K | — |
| 2026-03-03 | Coll Crespo Blas | Tax withheld | 12K | $20.99 |
| 2026-03-03 | Ma Yingli | Tax withheld | 11K | $20.99 |
| 2026-03-03 | Lin Xichen | Tax withheld | 19K | $20.99 |
| 2026-03-03 | Yoon Jun | Tax withheld | 22K | $20.99 |
| 2026-03-03 | Hall Ashley | Tax withheld | 4.8K | $20.99 |
| 2026-03-03 | Stevens Raymond C | Tax withheld | 53K | $20.99 |
| 2025-09-18 | Coll Crespo Blas | Tax withheld | 8.1K | $7.74 |
| 2025-09-18 | Hall Ashley | Tax withheld | 6.0K | $7.74 |
| 2025-07-01 | Coll Crespo Blas | Grant | 8.0K | — |
| 2025-07-01 | Ma Yingli | Tax withheld | 4.5K | $6.84 |
| 2025-07-01 | Lin Xichen | Tax withheld | 13K | $6.84 |
| 2025-07-01 | Coll Crespo Blas | Tax withheld | 1.4K | $6.84 |
| 2025-07-01 | Ma Yingli | Grant | 24K | — |
| 2025-07-01 | Lin Xichen | Grant | 57K | — |
| 2025-07-01 | Yoon Jun | Grant | 40K | — |
| 2025-07-01 | Yoon Jun | Tax withheld | 7.1K | $6.84 |
| 2025-07-01 | Stevens Raymond C | Grant | 90K | — |
| 2025-07-01 | Stevens Raymond C | Tax withheld | 16K | $6.84 |
| 2025-03-15 | Ma Yingli | Grant | 64K | — |
| 2025-03-15 | Lin Xichen | Grant | 81K | — |
| 2025-03-15 | Yoon Jun | Grant | 170K | — |
| 2025-03-15 | Stevens Raymond C | Grant | 340K | — |
| 2025-03-15 | Coll Crespo Blas | Grant | 117K | — |
| 2025-03-15 | Hall Ashley | Grant | 51K | — |
| 2025-03-01 | Ma Yingli | Tax withheld | 1.8K | $7.92 |
| 2025-03-01 | Stevens Raymond C | Tax withheld | 12K | $7.92 |
| 2025-03-01 | Yoon Jun | Tax withheld | 5.9K | $7.92 |
| 2025-03-01 | Coll Crespo Blas | Tax withheld | 1.2K | $7.92 |
| 2025-03-01 | Lin Xichen | Tax withheld | 6.4K | $7.92 |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT07400588 ↗ | Aleniglipron Phase 2 in Type 2 Diabetes Mellitus Obese, Obesity | PHASE2 | Active Not Recruiting | 2026-09-01 |
| NCT07169942 ↗ | Aleniglipron Phase 2 Body Composition Study Obesity, Overweight, or Chronic Weight Management | PHASE2 | Active Not Recruiting | 2026-08-01 |
| NCT06693843 ↗ | A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity Obesity, Overweight, or Chronic Weight Management | PHASE2 | Active Not Recruiting | 2025-10-24 |
| NCT07654361 ↗ | Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1) Obesity, Overweight | PHASE3 | Not Yet Recruiting | 2028-09-01 |
| NCT07654374 ↗ | A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2) Obesity, Overweight | PHASE3 | Not Yet Recruiting | 2028-09-01 |
| NCT06703021 ↗ | A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity Obesity, Overweight | PHASE2 | Completed | 2026-01-12 |
| NCT05762471 ↗ | Phase 1b/2a Study of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and Subjects With Type 2 Diabetes Mellitus Overweight or Obesity, Type2 Diabetes Mellitus | PHASE1/PHASE2 | Completed | 2024-04-11 |
| NCT06139055 ↗ | A Study of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese Participants Healthy Volunteers | PHASE1 | Unknown | 2024-03-01 |
| NCT05893043 ↗ | A Study of Multiple Ascending Doses of GSBR-1290 in Japanese and Non-Japanese Healthy Participants Healthy Volunteers | PHASE1 | Completed | 2023-06-28 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-06-18 | Shareholder vote | filing ↗ |
| 2026-05-07 | Material agreementResultsOtherExhibits | filing ↗ |
| 2026-04-15 | Exec/director changeReg FDExhibits | filing ↗ |
| 2026-03-16 | Reg FDOtherExhibits | filing ↗ |
| 2026-02-26 | ResultsExhibits | filing ↗ |
| 2026-01-05 | Material agreement | filing ↗ |
| 2025-12-10 | OtherExhibits | filing ↗ |
| 2025-12-08 | Reg FDOtherExhibits | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-18 | 2026-06-17 | 0001104659-26-075720 ↗ |
| 8-K | 2026-05-07 | 2026-05-07 | 0001104659-26-057226 ↗ |
| 10-Q | 2026-05-07 | 2026-03-31 | 0001104659-26-057230 ↗ |
| 8-K | 2026-04-15 | 2026-04-15 | 0001104659-26-043425 ↗ |
| 8-K | 2026-03-16 | 2026-03-16 | 0001104659-26-028023 ↗ |
| 8-K | 2026-02-26 | 2026-02-26 | 0001104659-26-020494 ↗ |
| 10-K | 2026-02-26 | 2025-12-31 | 0001104659-26-020562 ↗ |
| 8-K | 2026-01-05 | 2025-12-30 | 0001104659-26-000620 ↗ |
| 8-K | 2025-12-10 | 2025-12-09 | 0001104659-25-120015 ↗ |
| 8-K | 2025-12-08 | 2025-12-08 | 0001104659-25-119095 ↗ |
| 10-Q | 2025-11-06 | 2025-09-30 | 0001104659-25-107829 ↗ |
| 8-K | 2025-11-06 | 2025-11-06 | 0001104659-25-107740 ↗ |